LENVIMA (lenvatinib) has been on the market for 8 years, 8 months, and 13 days as of October 26, 2023.
LENVIMA received its initial approval from the U.S. Food and Drug Administration (FDA) on February 13, 2015, for the treatment of differentiated thyroid cancer. Subsequent approvals have expanded its indications.
Understanding LENVIMA's Market Presence
LENVIMA, a kinase inhibitor, has established a significant presence in the oncology market since its first FDA approval. Its journey began with an initial indication, and over time, its utility has broadened to address other challenging cancers.
Key Milestones in LENVIMA's Approval History
The timeline below highlights the pivotal moments in LENVIMA's regulatory journey, marking its entry and expansion in the market:
| Date | Approval Type | Indication |
|---|---|---|
| February 13, 2015 | Original Approval | Differentiated Thyroid Cancer |
| May 13, 2016 | Expanded Approval | Advanced Renal Cell Carcinoma |
This table illustrates that LENVIMA first became available to patients with differentiated thyroid cancer in early 2015, and its market reach extended to advanced renal cell carcinoma a little over a year later. Each approval represents a new patient population gaining access to this targeted therapy.
Impact of Market Longevity
A longer market presence often signifies:
- Established Efficacy: The drug has demonstrated consistent effectiveness across a significant patient base over time.
- Safety Profile Understanding: More extensive real-world data contributes to a deeper understanding of its long-term safety.
- Physician Familiarity: Healthcare providers become more experienced in prescribing and managing patients on the medication.
LENVIMA's time on the market has allowed for its integration into treatment paradigms for its approved indications, offering a crucial option for patients battling specific types of cancer.
